β-Nicotinamide mononucleotide, reduced form (disodium) (Standard)

β-Nicotinamide mononucleotide, reduced form (disodium) (Standard) is the analytical standard of β-Nicotinamide mononucleotide, reduced form (disodium) (HY-W615108B) . This product is intended for research and analytical applications. β-Nicotinamide mononucleotide, reduced form (NMNH) disodium is an orally active reduced version of β-Nicotinamide mononucleotide (HY-F0004) . β-Nicotinamide mononucleotide, reduced form disodium can significantly increase the levels of NAD+ and NADH, inhibit glycolysis, the tricarboxylic acid cycle, and cell growth, with its effects being dependent on nicotinamide mononucleotide adenylyltransferase (NMNAT) [1][2].

Product Specifications

CAS Number

[108347-85-9]

Target

Endogenous Metabolite; Reference Standards

Related Pathways

Metabolic Enzyme/Protease; Others

Field of Research

Cancer

Smiles

O[C@H]1[C@@H](O)[C@H](N2C=C(CC=C2)C(N)=O)O[C@@H]1COP(O[Na])(O[Na])=O

Molecular Formula

C11H15N2Na2O8P

Molecular Weight

380.20

References & Citations

[1]Liu Y, et al. Reduced Nicotinamide Mononucleotide (NMNH) Potently Enhances NAD+ and Suppresses Glycolysis, the TCA Cycle, and Cell Growth. J Proteome Res. 2021 May 7;20 (5) :2596-2606.|[2]Zapata-Pérez R, et al. Reduced nicotinamide mononucleotide is a new and potent NAD+ precursor in mammalian cells and mice. FASEB J. 2021 Apr;35 (4) :e21456.